

## KRAS Mutation Test – Results

### Sample Information

Patients first name	<b>Imaginary</b>	Patients last name	<b>Patient</b>
Date of birth (dd/mm/yyyy)	<b>01/01/1960</b>	Date tumour taken (dd/mm/yyyy)	<b>01/10/2010</b>
Patient ID No.	<b>00000</b>	Hospital No.	<b>00000</b>
Pathology Report No.	<b>00000</b>	Lab21 ID No.	<b>00000</b>
Referring Physician	<b>Dr Physician</b>		
Clinic/Hospital Address	<b>Cancer Clinic</b>		
Clinic/Hospital Address	<b>Imaginary Road</b>	Postcode	<b>00000</b>

### KRAS Biomarker Results

Amino Acid	Position	Mutation	Detected	Not Detected
Gly	12	Ala		✓
Gly	12	Asp		✓
Gly	12	Arg		✓
Gly	12	Cys		✓
Gly	12	Ser		✓
Gly	12	Val		✓
Gly	13	Asp		✓

The tumour in this sample carries wild-type KRAS and may respond to EGFR-based therapeutics



#### COMMENTS

Authorised by signature .....Lab Director..... Date Authorised ...1.../...10/...2010

Print name in BLOCK capitals      Lab Director

The KRAS mutation analysis test is CE marked under the European IVD Directive 98/79/EC. If you require any further information or assistance please contact Lab21 Customer Support:

**Lab21 Ltd** 184 Cambridge Science Park, Cambridge CB4 0GA, United Kingdom  
**T** 0845 6777199 (UK), +44 (0)1223 395450 (Intl) **F** +44 (0)1223 395451 **E** KRAS@lab21.com **W** www.lab21.com  
 Registered office: Lab21 Ltd, 184 Cambridge Science Park, Cambridge CB4 0GA. Registered number: 05382262.